SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 257 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $483 | +274.4% | 18,064 | +377.3% | 0.00% | +200.0% |
| Q1 2024 | $129 | -83.9% | 3,785 | -86.9% | 0.00% | -88.9% |
| Q3 2023 | $800 | +79.4% | 28,999 | +131.9% | 0.01% | +80.0% |
| Q4 2022 | $446 | -99.9% | 12,503 | +28.4% | 0.01% | +25.0% |
| Q3 2022 | $330,000 | -74.9% | 9,738 | -78.6% | 0.00% | -71.4% |
| Q2 2022 | $1,313,000 | -29.3% | 45,418 | -21.0% | 0.01% | 0.0% |
| Q1 2022 | $1,858,000 | -21.5% | 57,502 | -29.2% | 0.01% | +7.7% |
| Q4 2021 | $2,367,000 | +70.0% | 81,174 | +55.5% | 0.01% | +85.7% |
| Q3 2021 | $1,392,000 | +332.3% | 52,200 | +399.5% | 0.01% | +600.0% |
| Q2 2021 | $322,000 | +60.2% | 10,450 | +36.1% | 0.00% | 0.0% |
| Q1 2021 | $201,000 | -2.9% | 7,678 | -6.8% | 0.00% | 0.0% |
| Q4 2020 | $207,000 | -54.2% | 8,241 | -62.0% | 0.00% | -66.7% |
| Q3 2020 | $452,000 | -65.1% | 21,666 | -60.2% | 0.00% | -72.7% |
| Q2 2020 | $1,294,000 | +226.8% | 54,472 | +147.3% | 0.01% | +175.0% |
| Q1 2020 | $396,000 | +25.7% | 22,024 | +66.0% | 0.00% | +33.3% |
| Q4 2019 | $315,000 | +3.3% | 13,271 | +19.7% | 0.00% | 0.0% |
| Q3 2019 | $305,000 | -46.7% | 11,087 | -35.9% | 0.00% | -25.0% |
| Q2 2019 | $572,000 | +183.2% | 17,285 | +200.5% | 0.00% | +100.0% |
| Q1 2019 | $202,000 | -92.2% | 5,752 | -92.7% | 0.00% | -91.3% |
| Q4 2018 | $2,604,000 | +220.7% | 78,385 | +386.0% | 0.02% | +283.3% |
| Q3 2018 | $812,000 | -19.3% | 16,127 | -4.0% | 0.01% | -33.3% |
| Q2 2018 | $1,006,000 | +566.2% | 16,802 | +408.2% | 0.01% | +800.0% |
| Q1 2018 | $151,000 | -48.3% | 3,306 | -54.9% | 0.00% | -66.7% |
| Q4 2017 | $292,000 | -67.4% | 7,324 | -67.4% | 0.00% | -62.5% |
| Q3 2017 | $897,000 | +364.8% | 22,436 | +264.0% | 0.01% | +300.0% |
| Q1 2017 | $193,000 | -63.0% | 6,164 | -70.1% | 0.00% | -50.0% |
| Q4 2016 | $521,000 | +227.7% | 20,624 | +82.2% | 0.00% | +300.0% |
| Q3 2015 | $159,000 | +26.2% | 11,322 | +8.7% | 0.00% | 0.0% |
| Q1 2015 | $126,000 | +16.7% | 10,420 | -19.9% | 0.00% | 0.0% |
| Q4 2014 | $108,000 | – | 13,003 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $17,478,000 | 3.94% |
| ASHFORD CAPITAL MANAGEMENT INC | 1,124,405 | $36,341,000 | 3.91% |
| ARMISTICE CAPITAL, LLC | 3,100,000 | $100,192,000 | 1.94% |
| S&T BANK/PA | 316,326 | $10,224,000 | 1.54% |
| Bruce & Co., Inc. | 222,105 | $7,178,000 | 1.47% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 379,875 | $12,278,000 | 1.36% |
| RICE HALL JAMES & ASSOCIATES, LLC | 854,949 | $27,632,000 | 1.10% |
| Soleus Capital Management, L.P. | 251,000 | $8,112,000 | 1.05% |
| Parkman Healthcare Partners LLC | 108,954 | $3,521,000 | 1.03% |
| Aristotle Capital Boston, LLC | 1,258,067 | $40,661,000 | 1.03% |